Develops extracorporeal blood purification therapies designed to reduce excessive inflammation in critically ill patients. The company’s lead technology, the Selective Cytopheretic Device (SCD), is being studied for conditions such as acute kidney injury and pediatric inflammatory disorders in inten...
1 member of Congress has disclosed 1 trade in ICU, Inc. (ICU), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-01-23 | Chris Collins | buy | $15K – $50K |